BioFactura Awarded US Patent for its StableFastTM Biomanufacturing Platform

ROCKVILLE, Md.--(BUSINESS WIRE)--BioFactura, Inc. was awarded a US patent covering the core technologies of its proprietary StableFastTM Biomanufacturing Platform. The US Patent and Trademark Office allowed 32 claims broadly covering composition of matter, methods, commercial kits, and media formulations. StableFastTM was commercially launched earlier this year. The Company is actively marketing the system to companies developing biopharmaceuticals including novel compounds and biosimilars with a focus on therapeutic monoclonal antibodies.